The Biotechnology Innovation Organization (BIO) said President and CEO Jim Greenwood intends to step down after the 2020 election and will help transition a new leader. A former congressman from Pennsylvania, Greenwood was appointed head of BIO in 2005, succeeding the organization's founding president, Carl Feldbaum.
The FDA awarded 12 clinical trial research grants to companies and research institutions, totaling more than $15 million over the next four years, through the Orphan Products Clinical Trials Grants Program. Funded by Congress, the program is designed to encourage clinical development of drugs, biologics, medical devices and medical foods aimed at treating rare diseases. The FDA received a total of 89 grant applications, reviewed by rare disease experts, including members of academia. Industry awardees are: Chemocentryx Inc., of Mountain View, Calif., with $1 million over two years to fund a phase II study of avacopan for treating complement 3 glomerulopathy; Cumberland Pharmaceuticals Inc., of Nashville, Tenn., which will receive $1 million over three years to fund a phase II study of oral ifetroban in cardiomyopathy associated with Duchenne muscular dystrophy; Privo Technologies LLC, of Peabody, Mass., which was awarded $2 million over four years for a phase I/II study of a cisplatin patch (PRV-111) to treat oral cancer; and Targeted Therapy Technologies LLC, of Somerset, N.J., which will get $600,000 over three years to support a phase I study of episcleral topotecan to treat retinoblastoma.